We evaluated the effect of the calcium channel blocking agent, nifedipine, on esophageal dysfunction in 15 patients with progressive systemic sclerosis, using a double-blind, randomized, crossover, placebo-controlled manometric study. Nifedipine significantly decreased lower esophageal sphincter pressure in these patients; this reduced lower esophageal sphincter pressure may cause gastroesophageal reflux. Thus, nifedipine may have detrimental effects on progressive systemic sclerosis patients.The pathogenesis of esophageal dysfunction in progressive systemic sclerosis (scleroderma; PSS) has not been well elucidated (1,2). PSS is characterized by vascular and microvascular abnormalities (1-4), excessive fibroblastic activity (5,6), and collagen deposition in numerous organs (1,2,7). The possibility that the lesions in target organs are a reflection of a primary fibrous tissue overgrowth leading to secondary vascular compromise has not been ruled out. Nevertheless, a growing body of evidence based on studies of several organs involved in PSS suggests that the vascular system per se may be the primary target organ and that the lesions are a manifestation of focal ischemic injury resulting from functional, with or without accompanying structural, vascular disease (~4 , 8 4 4 ) .Nifedipine, a calcium channel blocking agent, is effective in the treatment of coronary vasospasm ( I 5-18). We (19-21) and others (22)(23)(24)(25) have shown that nifedipine is effective in the treatment of idiopathic Raynaud's phenomenon and Raynaud's phenomenon occurring with progressive systemic sclerosis. Thus, if a microvascular abnormality is a contributor to the pathogenesis of scleroderma, nifedipine may be useful in the treatment of patients with early disease.However, nifedipine may have detrimental effects caused by its direct action on the lower esophageal sphincter. The actions of nifedipine on smooth muscle cells are well documented (15)(16)(17)(18). Several studies have shown that the drug decreases the lower esophageal sphincter pressure (LESP) in patients with achalasia (26,27). If nifedipine also decreases the LESP in patients with progressive systemic sclerosis, this could lead to gastroesophageal reflux.In the present investigation, we used a controlled, double-blind, randomized, crossover manometric study to evaluate the effect of nifedipine on I5 patients with progressive systemic sclerosis and esophageal dysfunction. Our trial demonstrates that nifedipine significantly decreases the lower esophageal sphincter pressure in patients with PSS.
PATIENTS AND METHODSPatients. Fifteen patients with progressive systemic sclerosis and diffuse scleroderma were studied. All patients satisfied the American Rheumatism Association preliminary criteria for classification of definite systemic sclerosis (28). None of the patients had the CREST syndrome variant (calcinosis, Raynaud's phenomenon, esophageal dysmo-NIFEDIPINE IN PSS 49 1 tility, sclerodactyly, telangiectasias) of PSS (29). The presence of the esophageal symptoms of heartbur...